SVB Securities analyst Mani Foroohar maintained a Hold rating on Abeona Therapeutics (ABEO – Research Report) today and set a price target of $5.00. The company’s shares closed today at $4.66.
Foroohar covers the Healthcare sector, focusing on stocks such as Moderna, Alnylam Pharma, and Arrowhead Pharmaceuticals. According to TipRanks, Foroohar has an average return of -13.1% and a 41.88% success rate on recommended stocks.
Currently, the analyst consensus on Abeona Therapeutics is a Hold with an average price target of $5.00.
See the top stocks recommended by analysts >>
Based on Abeona Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $346 thousand and a GAAP net loss of $20.79 million. In comparison, last year the company had a GAAP net loss of $16 million
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ABEO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
Read More on ABEO:
- SurgePays Announces Second Quarter 2022 Financial Results
- Analysts Offer Insights on Healthcare Companies: Abeona Therapeutics (ABEO), Hookipa Pharma (HOOK) and RAPT Therapeutics (RAPT)
- ECN Capital Reports US$0.09 in Adjusted Net Income per Common Share in Q2-2022
- Dave Reports Second Quarter 2022 Results
- Field Trip Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financing
